高级检索
当前位置: 首页 > 详情页

Application of Zizao Yangrong Granules for Treating Targeted Drugs-Related Skin Xerosis: A Randomized Double-Blinded Controlled Study

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China [2]Beijing University of Chinese Medicine, Beijing, China [3]China-Japan Friendship Hospital, Beijing, China
出处:
ISSN:

关键词: Zizao Yangrong granules EGFRIs xerosis pruritus clinical trial

摘要:
Background:Dermatologic toxicities are the most common side effects associated with the targeted drugs epidermal growth factor receptor inhibitors (EGFRIs), in which xerosis commonly complicated by pruritus severely disturbs the quality of life. The study has observed the curative effect of Zizao Yangrong granules (ZYG) from Chishui Xuanzhu in the treatment of EGFRIs-related xerosis and pruritus, as well as evaluating the safety of the prescription.Methods:Patients (n = 68) who had xerosis after using EGFRIs were enrolled and then randomly divided into the treatment group and control group, respectively, receiving ZYG and placebo granules combined with vitamin E ointment. The intervention lasted 4 weeks. Changes in xerosis and pruritus were observed, and blood routine examination as well as liver and kidney functionare observed as safety indexes.The water content of skin and qualify of life were observed.Results:A total of 66 out of 68 patients finished the study with 34 patientsin each group. The effective rates of xerosis among the treatment group and control group were 84.8% and 69.7% after 2 weeks' treatment (P< .05), while they were 84.8% and 75.8% after 4 weeks' treatment (P< .05). The patients in the experimental group had better quality of life than that in the control group (P= .045).Conclusion:ZYG can effectively improve the skin dryness associated with EGFRIs, and significantly improve the quality of life of patients with good safety; however, larger randomized controlled trials are needed to verify these findings.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 全科医学与补充医学 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Q3 ONCOLOGY
最新[2023]版:
Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China
通讯作者:
通讯机构: [3]China-Japan Friendship Hospital, Beijing, China [*1]Department of Oncology, China-Japan Friendship Hospital, No. 2, Yinghua East Road, Chaoyang District, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)